Olivia Maynard summarises the recent Cochrane systematic review on motivational interviewing for smoking cessation, which concludes that motivational interviewing may assist people to quit smoking, but does not tell us much about the actual components of MI that optimise the success of the intervention.
[read the full story...]
Natasha Clarke publishes her debut Mental Elf blog about a new systematic review and meta-analysis investigating the risk of neuropsychiatric adverse events associated with the smoking cessation drug varenicline.
[read the full story...]
Consultant Psychiatrist Samei Huda provides a personal critique of the new NICE quality standard on psychosis and schizophrenia in adults. Read his thoughts and join the discussion!
[read the full story...]
Our resident Elf Economist, Chris Sampson, reports on a new systematic review of economic evaluations for borderline personality disorder. Are any cost-effective?
[read the full story...]
Andrew Jones and Chris Sampson report on a systematic review and economic evaluation of cytisine and varenicline for smoking cessation, which finds that both drugs are clinically effective compared with placebo.
[read the full story...]
It’s well known that individuals with mental illness smoke nearly twice as much as those without a psychiatric disorder (Gfroerer et al, 2013; Lasser et al, 2000), and are more addicted to nicotine, smoke more cigarettes per day, and find it more difficult to quit (Lasser et al, 2000). However, studies have shown that individuals [read the full story…]
While the organisation’s name may change frequently, currently National Institute for Health and Care Excellence (NICE), its role remains constant – to provide clear published guidance on the role of treatment options within the NHS. The publication of new NICE guidance represents a significant event as clinical recommendations shape the nature of provided care nationally [read the full story…]
People with serious mental health issues such as schizophrenia have higher rates of cigarette smoking than the general population, with estimates suggesting more than 50% are current smokers. When people in this population do manage to quit during treatment we then see particularly high rates of relapse after treatment ends. A new randomised control trial (Evins [read the full story…]
Smoking is a major cause of morbidity and mortality across the world and accounts for over 60% of deaths in people who do smoke. The World Health Organisation estimates that tobacco kills almost 6 million people per year, with 5 million as a result of direct tobacco use. Innovative treatment approaches aimed at improving smoking [read the full story…]
Smoking is a major preventable cause of morbidity and premature mortality throughout the world. There are an estimated 460,000 hospital admissions attributable to smoking in people aged over 35 every year, with an average annual cost to the NHS of £2.7 billion. Many strategies exist to help people give up smoking. The most common are [read the full story…]
